India "Must Amend Its Patent Act"

8 December 1997

India should amend its 1970 Patent Act to bring it into line with theWorld Trade Organization and Trade-Related Intellectual Property Rights, according to N Vittal, chairman of India's Public Enterprises Selection Board.

Developing countries like India should cultivate a positive, aggressive and pro-active posture with regard to Intellectual Property Rights, instead of a "defensive and reactionary negative posture," he said, speaking in New Delhi at a seminar organized by the Economic and Social Commission for Asia and the Pacific.

IPR and global competition are the key issues to be taken care of by developing countries while enhancing technology capability, according to Mr Vittal. If developing countries bring their IPR regime in tune with global standards, they may be able to build on their technological manpower, he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight